IMNN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMNN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Imunon's cash to debt ratio for the quarter that ended in Dec. 2024 was 5.16.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Imunon could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.
The historical rank and industry rank for Imunon's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Imunon's highest Cash to Debt Ratio was No Debt. The lowest was 1.31. And the median was 4.14.
The historical data trend for Imunon's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Imunon Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Cash-to-Debt | Get a 7-Day Free Trial |
![]() |
![]() |
2.77 | 7.45 | 5.23 | 9.67 | 5.16 |
Imunon Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Cash-to-Debt | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
9.67 | 6.50 | 3.82 | 8.15 | 5.16 |
For the Biotechnology subindustry, Imunon's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Imunon's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Imunon's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Imunon's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 5.873 | / | (0.452 | + | 0.687) | |
= | 5.16 |
Imunon's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 5.873 | / | (0.452 | + | 0.687) | |
= | 5.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imunon (NAS:IMNN) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Imunon's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Donald P Braun | director | C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648 |
Stacy Lindborg | director | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Michael H Tardugno | officer: Chief Executive Offier | 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364 |
James E Dentzer | director | C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Le Goff Corinne | director, officer: President and CEO | 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
Frederick J. Fritz | director | C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046 |
Kardaras Constantine John | officer: Chief Accounting Officer | C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648 |
Christine A Pellizzari | director | 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
Alberto R Martinez | director | C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648 |
Jeffrey Wayne Church | officer: Chief Financial Officer | |
Robert W Hooper | director | C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046 |
Andreas Voss | director | C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648 |
Egwu, Inc. Fka Egen, Inc. | 10 percent owner | 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806 |
Khursheed Anwer | officer: Chief Scientific Officer | C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648 |
Gregory L Weaver | director | 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
From GuruFocus
By GuruFocus Research • 08-16-2024
By Marketwired • 02-10-2025
By Marketwired • 02-27-2025
By GuruFocus Research • 08-16-2024
By Marketwired • 07-29-2024
By Marketwired • 10-30-2024
By Marketwired • 06-24-2024
By Marketwired • 12-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.